139 related articles for article (PubMed ID: 1881582)
1. Anti-rejection therapy in renal transplantation: Use of the monoclonal antibody OKT3.
Nicholson ML; Donnelly PK; Veitch PS; Bell PR
Nephrol Dial Transplant; 1991; 6(4):275-9. PubMed ID: 1881582
[TBL] [Abstract][Full Text] [Related]
2. Monoclonal antibody OKT3 therapy in pediatric kidney transplant recipients.
Leone MR; Barry JM; Alexander SR; Melvin T; Striegel J; Reller K; Henell KR; Kimball J; Funnell MB; Goldstein G
J Pediatr; 1990 May; 116(5):S86-91. PubMed ID: 2139465
[TBL] [Abstract][Full Text] [Related]
3. Use of a brief steroid trial before initiating OKT3 therapy for renal allograft rejection.
Thistlethwaite JR; Stuart JK; Mayes JT; Gaber AO; Stuart FP
Am J Kidney Dis; 1988 Feb; 11(2):94-8. PubMed ID: 3277413
[TBL] [Abstract][Full Text] [Related]
4. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants.
Ortho Multicenter Transplant Study Group
N Engl J Med; 1985 Aug; 313(6):337-42. PubMed ID: 2861567
[TBL] [Abstract][Full Text] [Related]
5. Monoclonal antibody (OKT3) rescue in refractory acute renal allograft rejection: report of 3 cases.
Suvanapha R; Laorpatanaskul S; Vajaraphongse R; Kitisin P; Srivatanawongsa V; Mulikamas S; Vajaraphongse K; Boonvisut S; Chusil S; Panmuong W
J Med Assoc Thai; 1989 Dec; 72(12):708-13. PubMed ID: 2628539
[TBL] [Abstract][Full Text] [Related]
6. Half dose of OKT3 is efficient in treatment of steroid-resistant renal allograft rejection.
Midtvedt K; Tafjord AB; Hartmann A; Eide TC; Holdaas H; Nordal KP; Draganov B; Sødal G; Leivestad T; Fauchald P
Transplantation; 1996 Jul; 62(1):38-42. PubMed ID: 8693541
[TBL] [Abstract][Full Text] [Related]
7. Concomitant low-dose cyclosporine and OKT3 therapy for renal transplant rejection.
Hricik DE; Zarconi J; Schulak JA
Transplant Proc; 1989 Feb; 21(1 Pt 2):1755-7. PubMed ID: 2652574
[No Abstract] [Full Text] [Related]
8. OKT3 treatment of steroid-resistant renal allograft rejection.
Thistlethwaite JR; Gaber AO; Haag BW; Aronson AJ; Broelsch CE; Stuart JK; Stuart FP
Transplantation; 1987 Feb; 43(2):176-84. PubMed ID: 3544373
[TBL] [Abstract][Full Text] [Related]
9. Improved results using OKT3 as induction immunosuppression in renal allograft recipients with delayed graft function.
Benvenisty AI; Cohen D; Stegall MD; Hardy MA
Transplantation; 1990 Feb; 49(2):321-7. PubMed ID: 2137654
[TBL] [Abstract][Full Text] [Related]
10. The reuse of OKT3 after previous rejection or induction therapy in cadaveric renal transplantation.
Shield CF; Hughes JD
Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):35-8. PubMed ID: 2510509
[TBL] [Abstract][Full Text] [Related]
11. OKT3 prophylaxis versus conventional drug therapy: single-center perspective, part of a multicenter trial.
Kahana L; Narvarte J; Ackermann J; LeFor W; Weinstein S; Wright C; deQuesada A; Baxter J; Shires D
Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):5-9. PubMed ID: 2510510
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of a second course of OKT3 monoclonal anti-T cell antibody for treatment of renal allograft rejection.
Norman DJ; Shield CF; Henell KR; Kimball J; Barry JM; Bennett WM; Leone M
Transplantation; 1988 Oct; 46(4):523-9. PubMed ID: 3140448
[TBL] [Abstract][Full Text] [Related]
13. A comparison of OKT3 monoclonal antibody and corticosteroids in the treatment of acute renal allograft rejection.
Deierhoi MH; Barber WH; Curtis JJ; Julian BA; Luke RG; Hudson S; Barger BO; Diethelm AG
Am J Kidney Dis; 1988 Feb; 11(2):86-9. PubMed ID: 3277412
[TBL] [Abstract][Full Text] [Related]
14. Influence of low-dose cyclosporine on the outcome of treatment with OKT3 for acute renal allograft rejection.
Hricik DE; Zarconi J; Schulak JA
Transplantation; 1989 Feb; 47(2):272-7. PubMed ID: 2493175
[TBL] [Abstract][Full Text] [Related]
15. OKT3 for the treatment of steroid-resistant acute renal allograft rejection.
Jogose JT; Bailey RR; Lynn KL; Robson RA; Wells JE
Nephron; 1997; 77(3):298-303. PubMed ID: 9375823
[TBL] [Abstract][Full Text] [Related]
16. A prospective comparison of murine monoclonal CD-3 (OKT3) antibody-based and equine antithymocyte globulin-based rejection prophylaxis in cardiac transplantation. Decreased rejection and less corticosteroid use with OKT3.
Renlund DG; O'Connell JB; Gilbert EM; Hammond ME; Burton NA; Jones KW; Karwande SV; Doty DB; Menlove RL; Herrick CM
Transplantation; 1989 Apr; 47(4):599-605. PubMed ID: 2523099
[TBL] [Abstract][Full Text] [Related]
17. The long-term effects of prophylactic OKT3 monoclonal antibody in cadaver kidney transplantation--a single-center, prospective, randomized study.
Abramowicz D; Goldman M; De Pauw L; Vanherweghem JL; Kinnaert P; Vereerstraeten P
Transplantation; 1992 Sep; 54(3):433-7. PubMed ID: 1412723
[TBL] [Abstract][Full Text] [Related]
18. The high failure rate of OKT3 in the treatment of acute renal allograft rejection resistant to steroids with or without antithymocyte globulin.
Davies SP; Brown EA; Woodrow DF; Phillips ME; Gower PE; Mee AD
Transplantation; 1991 Oct; 52(4):746-9. PubMed ID: 1926361
[No Abstract] [Full Text] [Related]
19. 15-Deoxyspergualin "rescue therapy" for methylprednisolone-resistant rejection of renal transplants as compared with anti-T cell monoclonal antibody (OKT3).
Okubo M; Tamura K; Kamata K; Tsukamoto Y; Nakayama Y; Osakabe T; Sato K; Go M; Kumano K; Endo T
Transplantation; 1993 Mar; 55(3):505-8. PubMed ID: 8456469
[TBL] [Abstract][Full Text] [Related]
20. Immunologic monitoring with Orthoclone OKT3 therapy.
Schroeder TJ; First MR; Hurtubise PE; Marmer DJ; Martin DM; Mansour ME; Melvin DB
J Heart Transplant; 1989; 8(5):371-80. PubMed ID: 2529358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
